This is a translation of the Swedish press release published 2022-12-15

Scientific article in leading international journal Pediatric Resarch, clinical study on 100 babies, preferential rights issue with new large shareholder, and important milestone achieved as of the certification according to ISO 13485 – CEO tells more in Neola Medical’s Investor Letter.

In the winter edition of the investor letter, CEO Hanna Sjöström tells more about the scientific article published in Pediatric Research that highlights the benefits of the technology used in the company’s medical device for continuous lung monitoring. Also, the finalized clinical study on 100 babies in Ireland is described. In the investor letter, the preferential rights issue is also presented along with the important milestone that was achieved this fall when the company’s quality management system was certified according to ISO 13485. Furthermore, Magnus Johnsson, Director Quality Assurance and Regulatory Affairs, comments on the certification and the importance of it.

Read the entire press release, including the investor letter, here (in Swedish): Press release